Drug delivery systems using mesoporous oxide films
View Patent ↗Sustained-release drug-delivery devices employing a mesoporous oxide coating that functions as a drug reservoir, and the use of mesoporous oxide coatings for improved adhesion of organic polymers to inorganic substrates.
1. A sustained-release drug delivery device comprising a structural element and a drug reservoir, wherein the drug reservoir comprises a coating applied to the surface of the structural element and wherein the coating comprises an inorganic mesoporous oxide with substantially continuously interconnected channels.
2. The sustained-release drug delivery device of claim 1 wherein the majority of the interconnected channels have a diameter of between 1-100 nm.
3. The sustained-release drug delivery device of claim 2 wherein the majority of the interconnected channels have a diameter of between 2 nm and 30 nm.
4. The sustained-release drug delivery device of claim 1 wherein the mesoporous oxide is a triblock copolymer-template-based mesoporous oxide.
5. The sustained-release drug delivery device of claim 4 wherein the mesoporous oxide is selected from the group consisting of: an oxide of silicon and an oxide of titanium.
6. The sustained-release drug delivery device of claim 1 wherein the interior surfaces of the interconnected channels are coated with an agent that modifies hydrophobicity or charge.
7. The sustained-release drug delivery device of claim 6 wherein agent that modifies hydrophobicity or charge comprises a silane coupling agent.
8. The sustained-release drug delivery device of claim 1 wherein the drug reservoir coating is applied to the surface of the structural element by a method selected from the group consisting of: dip-coating, spray coating, spin-coating and painting.
9. The sustained-release drug delivery device of claim 1 further comprising a drug loaded within the drug reservoir.
10. The sustained-release drug delivery device of claim 9 adapted for delivery of the drug for a period of at least 3 days.
11. The sustained-release drug delivery device of claim 10 adapted for delivery of the drug for a period of at least 7 days.
12. The sustained-release drug delivery device of claim 11 adapted for delivery of the drug for a period of at least 30 days.
13. The sustained-release drug delivery device of claim 9 wherein the drug is an anti-restenotic drug.
14. The sustained-release drug delivery device of claim 13 wherein the drug is a taxol-derived drug.
15. The sustained-release drug delivery device of claim 14 wherein the drug is selected from the group consisting of PACLITAXEL, SIROLIMUS, and TACROLIMUS.
16. The sustained-release drug delivery device of claim 13 wherein the drug delivery device is adapted for implantation into the vascular system of a subject.
17. The sustained-release drug delivery device of claim 16 wherein the drug delivery device comprises a stent.
18. The sustained-release drug delivery device of claim 17 wherein the total amount of drug loaded within the drug reservoir is between 1 and 1,000 micrograms per stent.
19. The sustained-release drug delivery device of claim 1 wherein the drug is selected from the group consisting of: an anti-inflammatory agent, an antimicrobial agent, and antineoplastic agent, and angiogenic agent, an anti-angiogenic agent, a thrombolytic agent, an antihypertensive agent, an anti-arrhythmic agent, a calcium channel blocker, a cholesterol-lowering agent, a psychoactive agent, an anti-depressive agent, an anti-seizure agent, a contraceptives, an analgesics, a bone growth factor, a bone remodeling factor, a neurotransmitter, and an opiate antagonist.